Viatris Inc (NASDAQ:VTRS)
| Market Cap | $22.50B+85.7% |
| Revenue (ttm) | $14.73B+4.3% |
| Net Income | -$607.80M+83.5% |
| EPS | -$0.53+82.9% |
| Shares Out | 1.15B |
| PE Ratio | n/a |
| Forward PE | 7.07 |
| Dividend | $0.48(2.45%) |
| Ex-Dividend Date | Nov 23, 2026 |
| Volume | 9,274,630 |
| Open | $19.99 |
| Previous Close | $19.88 |
| Day's Range | $19.43 - $20.09 |
| 52-Week Range | $10.39 - $21.20 |
| Beta | 0.87 |
| Analysts | Hold |
| Price Target | $21.00(+6.98%) |
| Earnings Date | Feb 25, 2027 |
About VTRS
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating VTRS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 23, 2026Ex-dividend date
- Feb 25, 2027Earnings report
$VTRS stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of VTRS by members of U.S. Congress
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Nov 18, 2025 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Nov 18, 2025 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Nov 17, 2025 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Mar 31, 2025 |
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Mar 31, 2025 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Mar 30, 2025 |
| Scott FranklinHouse / R | Sale$1.00K – $15.00K | May 20, 2021 |
| Scott FranklinHouse / R | Sale$100.00K – $250.00K | May 20, 2021 |
Recently reported changes in VTRS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VTRS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VTRS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
VTRS Revenue by Segment or Geography
| Brands | $2.46B | 30.35% |
| Developed Markets Segment | $2.22B | 27.32% |
| Generics | $1.27B | 15.70% |
| Emerging Markets Segment | $529.10M | 6.52% |
| Lipitor | $451.90M | 5.57% |
| Norvasc | $190.20M | 2.34% |
| EpiPen Auto-Injectors | $155.80M | 1.92% |
| Lyrica | $114.20M | 1.41% |
| Creon | $98.10M | 1.21% |
| Viagra | $94.10M | 1.16% |
| Influvac | $90.60M | 1.12% |
| Zoloft | $78.80M | 0.97% |
| Yupelri | $71.50M | 0.88% |
| Celebrex | $70.20M | 0.87% |
| Effexor | $63.90M | 0.79% |
| Xalabrands | $43.90M | 0.54% |
| Xanax | $36.60M | 0.45% |
| Amitiza | $36.40M | 0.45% |
| Dymista | $35.40M | 0.44% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New VTRS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VTRS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VTRS
| VOOVanguard S&P 500 ETF | $580.74M |
| VTIVanguard Morningstar Total Stock Market ETF | $548.13M |
| VBVanguard Morningstar Small-Cap ETF | $490.19M |
| VBRVanguard Morningstar Small-Cap Value ETF | $318.62M |
| IVViShares Core S&P 500 ETF | $307.62M |
| SPYState Street SPDR S&P 500 ETF | $278.28M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from VTRS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple analyst upgrades and price target increases, plus completion of Pacira acquisition and corporate recognition, drive predominantly bullish coverage.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| ADPV | Adaptiv Select ETF | 5.93% |
| DUSA | Davis Select U.S. Equity ETF | 5.75% |
| LSEQ | Harbor Long-Short Equity ETF (LSEQ) | 5.42% |
| IHE | iShares U.S. Pharmaceuticals ETF | 4.90% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 4.22% |
| RULE | Adaptive Core ETF | 3.87% |
| PJP | Invesco Pharmaceuticals ETF | 3.79% |
| DWLD | Davis Select Worldwide ETF | 3.74% |
| MVPA | Miller Value Partners Appreciation ETF | 3.28% |
| CVSM | CresAlta Small and Mid-Cap ETF | 3.06% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 2.49% |
| ABIG | Argent Large Cap ETF | 2.48% |
Weight is the stock’s share of each fund’s holdings.
